bosentan anhydrous has been researched along with Abnormalities, Drug-Induced in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beacham, S; Bouley, L; Edfjall, C; Herrmann, P; Kempff, M; Oster, L; Raineri, M; Segal, ES; Valette, C; van Lierop, C | 1 |
1 review(s) available for bosentan anhydrous and Abnormalities, Drug-Induced
| Article | Year |
|---|---|
Risk management strategies in the postmarketing period : safety experience with the US and European bosentan surveillance programmes.
Topics: Abnormalities, Drug-Induced; Antihypertensive Agents; Bosentan; Europe; Humans; Liver; Product Surveillance, Postmarketing; Risk Management; Safety; Sulfonamides; United States | 2005 |